Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 8/20 | 1.00 |
| ▸ | F2 | P00734 | 7/20 | 1.00 |
| ▸ | PLAU | P00749 | 2/20 | 1.00 |
| ▸ | F10 | P00742 | 3/20 | 0.76 |
| ▸ | FURIN | P09958 | 1/20 | 0.76 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.73 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.73 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.73 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17084494 | 1.00 | ST14 (1.00) | ST14F2PLAUF10FURIN | |
| SCHEMBL3085721 | 0.91 | F2 (0.83) | ST14F2PLAUF10FURIN | |
| SCHEMBL19286912 | 0.91 | ST14 (0.83) | ST14F2PLAUF10FURIN | |
| SCHEMBL13270794 | 0.89 | ST14 (0.79) | ST14F2PLAUF10FURIN | |
| SCHEMBL20364177 | 0.89 | ST14 (0.79) | ST14F2PLAUF10FURIN | |
| SCHEMBL6579180 | 0.87 | F2 (1.00) | ST14F2PLAUF10FURIN | |
| SCHEMBL851834 | 0.85 | ST14 (1.00) | ST14F2PLAUF10FURIN | |
| SCHEMBL14519335 | 0.84 | F2 (0.72) | ST14F2PLAUF10FURIN | |
| SCHEMBL537030 | 0.83 | LMNA (0.77) | ST14F2PLAUF10PRSS1 | |
| SCHEMBL3791103 | 0.82 | ST14 (1.00) | ST14F2PLAUF10FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299519-B2 | Host cells and methods using a repressor polypeptide and an inducible promoter for gene expression | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | claimed |
| US-20200262875-A1 | Host cells and methods using a repressor polypeptide and an inducible promoter for gene expression | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-20 | — | — | US | claimed |
| US-20090131342-A1 | Nitrosated and/or nitrosylated compounds, compositions and methods of use | NITROMED, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-20070099906-A1 | Combinations for the treatment of noeplastic disorders | COMBINATORX, INC. | 2007-05-03 | — | — | US | claimed |
| EP-1732527-A2 | USE AND ADMINISTRATION OF BACTERIAL EFFLUX PUMP INHIBITORS | MPEX PHARMACEUTICALS, INC. (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060276473-A1 | Use and administration of bacterial efflux pump inhibitors | REMPEX PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1718286-A2 | NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005089738-A2 | USE AND ADMINISTRATION OF BACTERIAL EFFLUX PUMP INHIBITORS | MPEX PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1339399-A2 | COMBINATIONS OF DRUGS (E.G., CHLORPROMAZINE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | Combinatorx, Incorporated (US) | 2003-09-03 | — | — | EP | claimed |
| US-20030105066-A1 | Nitrate salts of antimicrobial agents | NICOX S.A. (FR) | 2003-06-05 | — | — | US | claimed |
| EP-1309354-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | Rutgers, The State University (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | ZALICUS INC. | 2002-11-07 | — | — | US | claimed |
| EP-1253924-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX S.A. (FR) | 2002-11-06 | — | — | EP | claimed |
| WO-2002058684-A2 | COMBINATIONS OF DRUGS (E.G., CHLORPROMAZINE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002058697-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | POLYMERIX CORPORATION | 2002-06-13 | — | — | US | claimed |
| WO-2002009768-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY (US) | 2002-02-07 | — | — | WO | claimed |
| WO-2001054691-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX, S.A. (FR) | 2001-08-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | DHFR, DPYD, VHL | ST14 1069/4885F2 2251/4885PLAU 739/4885 |
| US-20090131342-A1 | Nitrosated and/or nitrosylated compounds, compositions and methods of use | LTC4S, LTB4R2, LTB4R | ST14 3481/4885F2 2627/4885PLAU 2859/4885 |
| US-20060276473-A1 | Use and administration of bacterial efflux pump inhibitors | ABCB11, ABCC1, ABCB1 | ST14 2585/4885F2 4870/4885PLAU 2604/4885 |
| US-20070099906-A1 | Combinations for the treatment of noeplastic disorders | NOP56, XPOT, NPM1 | ST14 2830/4885F2 2263/4885PLAU 1572/4885 |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | NPEPPS, PAICS, PUF60 | ST14 387/4885F2 964/4885PLAU 171/4885 |
| US-20030105066-A1 | Nitrate salts of antimicrobial agents | NOS1, NOS3, NOS2 | ST14 2219/4885F2 4461/4885PLAU 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.